ciltacabtagene autoleucel at a glance
Medicine class
Autologous, BCMA-directed CAR T-cell therapy.
Licensed use
Relapsed and refractory multiple myeloma in eligible adults previously treated with an immunomodulatory agent and proteasome inhibitor, whose disease progressed and is resistant to lenalidomide.
Administration
Given into a vein by trained staff at a qualified treatment centre; it is not taken at home.
After treatment
Close monitoring and access to the treatment centre are essential because serious immune and neurological reactions can be delayed.
What is ciltacabtagene autoleucel used for?
UK-licensed use:
Adults with relapsed and refractory multiple myeloma who have received previous therapy including an immunomodulatory agent and a proteasome inhibitor, whose disease progressed on their last therapy and is refractory to lenalidomide.
How does ciltacabtagene autoleucel work?
The patient’s T cells are modified to carry a receptor with two BCMA-binding parts. They recognise BCMA on myeloma cells, become activated and kill the targeted cells.
How to take ciltacabtagene autoleucel
It is prepared from the patient’s collected white blood cells and given intravenously at a qualified centre. Staff confirm that the patient’s identity matches the patient-specific product. Carry the alert card, remain near the treatment centre as instructed and attend planned monitoring appointments.
Tell the team about infection symptoms or new health problems before treatment.
Do not drive or operate dangerous machinery during the initial eight weeks or whenever neurological symptoms occur.
Do not donate blood, organs, tissues or cells for transplantation after treatment.
ciltacabtagene autoleucel side effects
Common or expected effects
- Fever, chills and cytokine release syndrome
- Low white blood cells, red blood cells or platelets
- Infections, including respiratory infections and pneumonia
- Fatigue, headache and musculoskeletal pain
- Diarrhoea, nausea, vomiting, constipation or reduced appetite
- Low immunoglobulin levels
- Low blood pressure, fast heartbeat or reduced blood oxygen
- Confusion, reduced alertness, speech changes, dizziness or movement problems
Get urgent medical advice
- Cytokine release syndrome, causing fever, chills, breathing difficulty, fast heartbeat, dizziness or low blood pressure
- Neurological toxicity, including confusion, reduced consciousness, speech or writing difficulty, seizures, weakness, tremor, personality change or altered walking
- Serious infection or sepsis, particularly fever with low blood-cell counts
- Severe bleeding or unusual bruising
- Severe allergic reaction, including swelling, breathing difficulty or collapse
- Persistent severe diarrhoea or abdominal pain, which may indicate immune-mediated enterocolitis
- New neurological symptoms appearing weeks or months later
ciltacabtagene autoleucel in pregnancy
There are no adequate pregnancy data, and fetal harm cannot be excluded. Pregnancy must be excluded before treatment. Use is not recommended during pregnancy or without effective contraception. Discuss pregnancy and contraception with the specialist team, including requirements related to preparatory chemotherapy.
ciltacabtagene autoleucel while breastfeeding
It is unknown whether ciltacabtagene autoleucel passes into human milk. A risk to the infant cannot be excluded, so discuss breastfeeding with the treating specialist.
ciltacabtagene autoleucel interactions
Formal interaction studies are limited. The specialist team should review all medicines and vaccines.
Live viral vaccines
Avoid before preparatory chemotherapy, during treatment and until immune recovery. Agree vaccination plans with the specialist team.
Corticosteroids and other medicines that suppress T-cell function
They may interfere with CAR T-cell activity. Their use should be directed by the specialist team, including when needed to manage toxicity.
Medicines that stimulate T-cell function
Co-administration has not been adequately studied, and its effects are unknown.
Common questions about ciltacabtagene autoleucel
Answers are fully visible for fast scanning and source review.
What is ciltacabtagene autoleucel made from?
The patient’s own T cells, collected and genetically modified to recognise BCMA on myeloma cells.
Why must it be given in a specialist centre?
It requires patient-specific handling and close monitoring for potentially life-threatening immune, neurological, infectious and blood-related complications.
Can neurological effects be delayed?
Yes. Confusion, speech or writing changes, weakness, tremor, personality changes and movement problems may appear after the initial recovery period and require urgent assessment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.